Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer
Neoplasms, Ovarian

Interventions: Drug: topotecan
Drug: CARBOPLATIN

First Posted Date: 2006-04-20

Last Posted Date: 2012-11-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 77

Registration Number: NCT00316173

Locations: 🇨🇦
GSK Investigational Site, Quebec, Canada

Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients

Phase 1

Completed

Conditions: Stage IV Breast Cancer
Ovarian Epithelial Cancer Stage III
Stage IV Ovarian Cancer

First Posted Date: 2006-04-20

Last Posted Date: 2011-02-18

Lead Sponsor: Swedish Medical Center

Target Recruit Count: 30

Registration Number: NCT00316407

Locations: 🇺🇸
Swedish Medical Center Cancer Institute, Seattle, Washington, United States
🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States

First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin

Phase 2

Completed

Conditions: Lung Cancer, Small Cell

Interventions: Drug: topotecan
Drug: carboplatin

First Posted Date: 2006-04-20

Last Posted Date: 2015-05-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 33

Registration Number: NCT00316186

Locations: 🇵🇱
GSK Investigational Site, Poznan, Poland

First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: enzastaurin
Drug: docetaxel
Drug: pemetrexed
Drug: carboplatin

First Posted Date: 2006-03-30

Last Posted Date: 2021-05-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 218

Registration Number: NCT00308750

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States

Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Small Cell Lung
Lung Cancer

First Posted Date: 2006-03-29

Last Posted Date: 2010-06-22

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 55

Registration Number: NCT00308529

Locations: 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States

and more 1 locations

Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Small Cell

Interventions: Drug: Topotecan
Drug: carboplatin

First Posted Date: 2006-03-22

Last Posted Date: 2013-01-31

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 61

Registration Number: NCT00305942

Locations: 🇺🇸
Family Cancer Center, Collierville, Tennessee, United States
🇺🇸
Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
🇺🇸
Montana Cancer Institute Foundation, Missoula, Montana, United States

and more 13 locations

Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma

Not Applicable

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2006-03-17

Last Posted Date: 2014-01-28

Lead Sponsor: Universitätsklinikum Hamburg-Eppendorf

Target Recruit Count: 567

Registration Number: NCT00303810

Locations: 🇩🇪
University Medical Center Hamburg - Eppendorf, Hamburg, Germany

Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors

Phase 1

Completed

Conditions: Anaplastic Oligoastrocytoma
Anaplastic Oligodendroglioma
Mixed Glioma
Oligoastrocytoma

Interventions: Drug: Carboplatin
Drug: Etoposide
Drug: Etoposide Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mannitol
Drug: Melphalan
Other: Quality-of-Life Assessment
Drug: Sodium Thiosulfate

First Posted Date: 2006-03-17

Last Posted Date: 2022-03-17

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 33

Registration Number: NCT00303849

Locations: 🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors
Childhood Germ Cell Tumor
Kidney Cancer
Liver Cancer
Neuroblastoma
Ovarian Cancer
Sarcoma
Unspecified Childhood Solid Tumor, Protocol Specific

First Posted Date: 2006-03-17

Last Posted Date: 2012-03-15

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 26

Registration Number: NCT00303940

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Pegylated liposomal doxorubicin
Drug: Carboplatin
Drug: trastuzumab

First Posted Date: 2006-03-15

Last Posted Date: 2016-11-03

Lead Sponsor: US Oncology Research

Target Recruit Count: 136

Registration Number: NCT00303108

Locations: 🇺🇸
Missouri Cancer Associates, Columbia, Missouri, United States
🇺🇸
Texas Cancer Center, Arlington, Texas, United States
🇺🇸
Hematology Oncology Associates of IL, Chicago, Illinois, United States

and more 50 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy